目次

1. Introduction to KRAS Inhibitors
1.1 Development of KRAS Inhibitors
1.2 Mechanism Of Action

2. Role of KRAS Inhibitors in Cancer Therapy
2.1 Lung Cancer
2.2 Pancreatic Cancer
2.3 Colorectal Cancer
2.4 Other Cancers

3. Lumakras - First Approved KRAS Inhibitor
3.1 Overview and Patent Insight
3.2 Dosage and Price Analysis
3.3 Sales Analysis

4. Krazati - Second Approved KRAS Inhibitor
4.1 Overview and Patent Insight
4.2 Dosage and Price Analysis

5. Global KRAS Inhibitor Market Outlook
5.1 Current Market Scenario
5.2 Future Market Opportunity

6. KRAS Inhibitor Market Regional Analysis
6.1 US
6.2 UK
6.3 China
6.4 Europe
6.5 Japan
6.6 South Korea
6.7 Canada

7. Global KRAS Inhibitors Clinical Pipeline Overview
7.1 By Country
7.2 By Phase
7.3 By Company
7.4 By Indication
7.5 By Patient Segment

8. Global KRAS Inhibitors Clinical Pipeline By Company, Indication and Phase
8.1 Research
8.2 Preclinical
8.3 Phase-I
8.4 Phase-I/II
8.5 Phase-II
8.6 Phase-III

9. Marketed KRAS Inhibitors Clinical Insight
9.1 Sotorasib - Amgen
9.2 Adagrasib - Mirati Therapeutics

10. Global KRAS Inhibitors Market Dynamics
10.1 Market Drivers and Opportunities for KRAS Inhibitors
10.2 Challenges for KRAS Inhibitors Market

11. Competitive Landscape
11.1 Array BioPharma
11.2 Applied Pharmaceutical Science
11.3 Amgen
11.4 AnBogen Therapeutics
11.5 Ascentage Pharma
11.6 AstraZeneca
11.7 BridgeBio Pharma
11.8 Boehringer Ingelheim
11.9 Erasca
11.10 Carmot Therapeutics
11.11 FogPharma
11.12 Frontier Medicines
11.13 Jacobio Pharmaceuticals
11.14 Jemincare
11.15 Jiangsu Hansoh Pharmaceutical
11.16 Jiangsu Hengrui Medicine Co.
11.17 Leidos Biomedical Research
11.18 Mirati Therapeutics
11.19 REVOLUTION Medicines
11.20 Roche
11.21 Shanghai Euregen Biopharma
11.22 Shanghai Yingli Pharmaceutical
11.23 Singh Biotechnology
11.24 Suzhou Genhouse Bio
11.25 Suzhou Zelgen Biopharmaceuticals

List of Figures & Tables
Figure 1-1: RAS Mutation - Frequency of KRAS Mutation v/s HRAS and NRAS Mutations
Figure 1-2: Historical Development of KRAS Inhibitors
Figure 1-3: General Mechanism of KRAS Inhibitors against Cancer
Figure 1-4: Targeting Approaches of KRAS Inhibitors
Figure 1-5: Direct Targeting of Mutant KRAS
Figure 1-6: Targets for Modifying the KRAS Membrane Association
Figure 2-1: KRAS Mutational Frequency by Organs (%)
Figure 2-2: Roles of KRAS Inhibitors in Cancer Treatment
Figure 2-3: Global - Estimated Newly Diagnosed Lung Cancer Cases and Deaths (Millions), 2020
Figure 2-4: Global - Lung Cancer Incidence by Type (%), 2020
Figure 2-5: Impact of KRAS Inhibitor on Lung Cancer
Figure 2-6: Investigational KRAS Inhibitors for Lung Cancer
Figure 2-7: RMC-6291 Phase I Trial - Study Initiation and Expected Completion Year
Figure 2-8: Revolution Medicines - KRAS inhibitors and Status
Figure 2-9: JAB-21822 Phase I/II Monotherapy Trial - Study Initiation and Expected Completion Year
Figure 2-10: JAB-21822 Phase I/II Monotherapy and Combination Therapy Trial - Study Initiation and Expected Completion Year
Figure 2-11: JAB-21822 Phase I/II Combination Therapy Trial - Study Initiation and Expected Completion Year
Figure 2-12: JAB-21822 Phase I/II Co Mutation Trial - Study Initiation and Expected Completion Year
Figure 2-13: Global - Estimated Newly Diagnosed Pancreatic Cancer Cases and Deaths, 2020
Figure 2-14: Ideal Targets of Inhibiting KRAS Mutation of Pancreatic Cancer
Figure 2-15: Role of KRAS Inhibitors in Pancreatic Cancer
Figure 2-16: Investigational KRAS Inhibitors for Pancreatic Cancer
Figure 2-17: siG12D LODER Phase II Trial - Study Initiation and Expected Completion Year
Figure 2-18: iExosomes Phase I Trial - Study Initiation and Expected Completion Year
Figure 2-19: HBI-2438 Phase I Trials - Study Initiation and Expected Completion Year
Figure 2-20: KRAS mTCR PBL Phase I/II Trials - Study Initiation and Expected Completion Year
Figure 2-21: Global - Estimated Newly Diagnosed Colorectal Cancer Cases and Deaths (Millions), 2020
Figure 2-22: Global - New Colorectal Cancer Incidences By Type (%), 2020
Figure 2-23: Ideal Targets for Inhibiting KRAS Mutation of Pancreatic Cancer
Figure 2-24: Investigational KRAS Inhibitors for Colorectal Cancer
Figure 2-25: KRAS mTCR PBL Phase I/II Trials - Study Initiation and Expected Completion Year
Figure 2-26: IBI351 Phase Ib Trial - Study Initiation and Expected Completion Year
Figure 2-27: Global - Estimated Newly Diagnosed Leukemia and Lymphoma Cases and Deaths (Millions), 2020
Figure 2-28: US - Estimated New Hodgkin and Non Hodgkin Lymphoma Cases and Deaths (Millions), 2022
Figure 2-29: Frequency of KRAS Mutation in Hematological Cancer (%)
Figure 2-30: Global - Newly Diagnosed Prostate Cancer Cases and Deaths (Millions), 2020
Figure 2-31: Global - Number of Newly Diagnosed Gastric Cancer Cases and Deaths (Millions), 2020
Figure 2-32: Global - Number of Newly Diagnosed Endometrial Cancer Cases and Deaths (Millions), 2020
Figure 2-33: Global - Gynecological Cancer Incidence By Type, 2020
Figure 2-34: Global - Newly Diagnosed Cases and Deaths related to Brain Cancer (Millions), 2020
Figure 3-1: Lumakras - Approval Year By Region
Figure 3-2: US - Lumakras Patent Filing and Expiration Year
Figure 3-3: US - Lumakras FDA Approval and Patent Exclusivity Year
Figure 3-4: US - Number Of Physicians Prescribing Lumakras Annually, 2021 and 2022
Figure 3-5: US - Number Of Patients Getting Prescribed Lumakras Annually, 2021 and 2022
Figure 3-6: US - Number Of Physicians Prescribing Lumakras Annually Quarterly, 2022
Figure 3-7: US - Number Of Patients Getting Prescribed Lumakras Quarterly, 2022
Figure 3-8: US - Price for 240 Tablet Lumakras Supply and Price Per Unit of 120mg Tablet (US$), February’2023
Figure 3-9: UK - Price for 240 Tablet Lumakras Supply and Price Per Unit of 120mg Tablet (GBP/US$), February’2023
Figure 3-10: US - Monthly and Annual Treatment Cost with Lumakras (US$), February’2023
Figure 3-11: Lumakras - Recommended Initial and Reduced Dose (mg/day)
Figure 3-12: Global - Lumakras/Lumykras Annual Sales (US$ Million), 2021-2022
Figure 3-13: Global - Lumakras/Lumykras Sales by Region (US$ Million), 2022
Figure 3-14: Global - Lumakras/Lumykras Annual Sales by Region (%), 2022
Figure 3-15: Global - Lumakras/Lumykras Quarterly Sales (US$ Million), 2022
Figure 3-16: US - Lumakras/Lumykras Annual Sales (US$ Million), 2021 - 2022
Figure 3-17: US - Lumakras/Lumykras Quarterly Sales (US$ Million), 2022
Figure 3-18: ROW - Lumakras/Lumykras Quarterly Sales (US$ Million), 2022
Figure 4-1: US - Adagrasib Patent Filing and Publication Year
Figure 4-2: US - WAC Price for 180-Tablet Krazati Supply and Price Per Unit of 200mg Tablet (US$), January’2023
Figure 4-3: Krazati - Recommended Initial and Reduced Dose (mg/day)
Figure 4-4: US - Estimated Monthly and Annual Treatment Cost with Krazati (US$), January’2023
Figure 5-1: Global - Cancer Incidences and Deaths (Million), 2020
Figure 5-2: Global - KRAS Inhibitor Market (US$ Million), 2021 and 2022
Figure 5-3: Global - KRAS Inhibitor Market Size by Region (US$ Million), 2022
Figure 5-4: Global - KRAS Inhibitor Market Size (US$ Million), 2023 - 2029
Figure 6-1: US - Cancer Incidences and Deaths (Million), 2020 and 2025
Figure 6-2: US vs. ROW - KRAS Inhibitor Market Size (US$ Million), 2022
Figure 6-3: US vs. ROW - KRAS Inhibitor Market Size (%), 2022
Figure 6-4: US - KRAS Inhibitor Market Size (US$ Million), 2022 - 2029
Figure 6-5: UK - Cancer Incidences and Deaths, 2020 and 2025
Figure 6-6: UK - KRAS Inhibitor Market Size (US$ Million), 2022 - 2029
Figure 6-7: China - Cancer Incidences and Deaths (Million), 2020 and 2025
Figure 6-8: China - KRAS Inhibitor Market Size (US$ Million), 2022 - 2029
Figure 6-9: Europe - Cancer Incidences and Deaths (Million), 2020 and 2025
Figure 6-10: Europe - KRAS Inhibitor Market Size (US$ Million), 2022 - 2029
Figure 6-11: Japan - Cancer Incidences and Deaths (Million), 2020 and 2025
Figure 6-12: Japan - KRAS Inhibitor Market Size (US$ Million), 2022 - 2029
Figure 6-13: South Korea - Cancer Incidences and Deaths (Million), 2020 and 2025
Figure 6-14: South Korea - KRAS Inhibitor Market Size (US$ Million), 2022 - 2029
Figure 6-15: Canada - Cancer Incidences and Deaths (Million), 2020 and 2025
Figure 6-16: Canada - KRAS Inhibitor Market Size (US$ Million), 2022 - 2029
Figure 7-1: Global - KRAS Protein inhibitors Clinical Trials by Country, 2023 -2029
Figure 7-2: Global - KRAS Protein inhibitors Clinical Trials by Phase, 2023 -2029
Figure 7-3: Global - KRAS Protein inhibitors Clinical Trials by Company, 2023 -2029
Figure 7-4: Global - KRAS Protein inhibitors Clinical Trials by Indication, 2023 -2029
Figure 7-5: Global - KRAS Protein inhibitors Clinical Trials by Patient Segment, 2023 -2029
Figure 10-1: Drivers for KRAS Inhibitor Market
Figure 10-2: Challenges for KRAS Inhibitor Market
Figure 10-3: US - Estimated Monthly Treatment Cost of Lumakras and Krazati v/s Other Cell Signal Targeting Therapeutics